Replies to post #412969 on Amarin Corp Plc (AMRN)

[IgnoranceIsBliss]

I think because COVID basically lost its legs by last winter, Kaiser lost interest.

[rosemountbomber]

Assume this is no reason to lie, Raf apparently got a reply from Amarin IR, while not explaining the reason for the Mitigate termination, said that it was not related to safety, efficacy or quality concerns.


"[e-mail]
to Me & 1 more
Today, 1:37 PM
1h MITIGATE was an Investigator Initiated Trial conducted at Kaiser Permanente Northern California that studied
Amarin's product VASCEPA/VAZKEPA (icosapent ethyl). Investigator Initiated Trials, or ITs, are run by the
investigators who initiate them. Recently Amarin was notified by Kaiser Permanente that the trial had been terminated prior to analysis of the study data. The study was not terminated or stopped due to any safety, efficacy or quality concerns
related to VASCEPA/VAZKEPA (icosapent ethyl). Amarin will have no further comment on the MITIGATE study or the circumstances surrounding the study's
termination.
Thank you,
Amarin IR"

Further I noticed that today (I believe) Raf was posting on ST that "Mitigate was stolen" from us and that he believes it was fraud. Not really sure I understand exactly what he is implying. If anyone can elucidate, it would be appreciated.

[ORBAPU]

So the IRB is in fact a KP internal review board. They answer to the people who sign their paychecks. The DSMC is independent and will review safety, efficacy, and futility.

Given Amarin’s response to Raf, my conclusion is that KP lost interest or determined the study results would not serve their business objectives.

[Denisk]

ORBAPU L MALDAGUE north40000 rosemountbomber

Mitigate, Mitigate, Mitigate: Not sponsored or funded by the NIH or FDA:
This was never intended as a clinical trial to reveal additional positive medical results for using Vascepa/ Vazkepa was only done to promote the distribution and sale of Vascepa to KP customers and patients.
Total waste of time to talk about it.
Enough wityh this topic. Going nowhere.